No Data
RBC: The first half of the year is expected to welcome positive catalysts. COMPASS Pathways (CMPS.US) and 12 other mid-small pharmaceutical stocks are worth a look.
RBC believes that some important catalysts for small and mid-cap Biotechnology companies in the first quarter of 2025 may have a significant impact on the Stocks it covers.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Design Therapeutics Updates Corporate Presentation for Investors
Despite Design Therapeutics' Pullback, Insiders Still Gained US$39k
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Top Premarket Decliners
. Safe travels tomorrow 
